Expert consensus on rational clinical application of amphotericin B deoxycholate (2022)
Amphotericin B (AmB) is an antifungal drug with the broadest spectrum and the most robust antifungal activity in clinical practice. Although there are many kinds of lipid formulations which significantly reduce the toxicity and side effects of amphotericin B deoxycholate (AmBd), AmBd will still play an important clinical role in China for a long time since lipid formulations are substantially more expensive. To standardize the clinical application of AmBd, well-known experts in this field were invited to reach a consensus on the antifungal properties, pharmacokinetic characteristics, dosage regimen, clinical application, prevention and treatment of adverse reactions of AmBd.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Zhonghua yi xue za zhi - 103(2023), 16 vom: 25. Apr., Seite 1173-1183 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Expert Panel for Clinical Rational Application of Amphotericin B Deoxycholate [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 25.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn112137-20221206-02578 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355911256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355911256 | ||
| 003 | DE-627 | ||
| 005 | 20231226065340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn112137-20221206-02578 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355911256 | ||
| 035 | |a (NLM)37087401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a Expert Panel for Clinical Rational Application of Amphotericin B Deoxycholate |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expert consensus on rational clinical application of amphotericin B deoxycholate (2022) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 25.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Amphotericin B (AmB) is an antifungal drug with the broadest spectrum and the most robust antifungal activity in clinical practice. Although there are many kinds of lipid formulations which significantly reduce the toxicity and side effects of amphotericin B deoxycholate (AmBd), AmBd will still play an important clinical role in China for a long time since lipid formulations are substantially more expensive. To standardize the clinical application of AmBd, well-known experts in this field were invited to reach a consensus on the antifungal properties, pharmacokinetic characteristics, dosage regimen, clinical application, prevention and treatment of adverse reactions of AmBd | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a amphotericin B, deoxycholate drug combination |2 NLM | |
| 650 | 7 | |a 87687-70-5 |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 0 | |a Infectious Diseases Society of China |e verfasserin |4 aut | |
| 700 | 0 | |a Chinese Society of Bacterial Infection and Resistance |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 103(2023), 16 vom: 25. Apr., Seite 1173-1183 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2023 |g number:16 |g day:25 |g month:04 |g pages:1173-1183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112137-20221206-02578 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2023 |e 16 |b 25 |c 04 |h 1173-1183 | ||